Thandassery Ragesh B, Goenka Usha, Goenka Mahesh K
Institute of Gastroscience, Apollo Gleneagles Hospital, Kolkata, West Bengal, India.
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S104-11. doi: 10.1016/j.jceh.2014.03.046. Epub 2014 Apr 1.
Percutaneous local ablation (PLA) techniques are currently considered as the best treatment option for patients with early-stage hepatocellular carcinoma (HCC) who are not candidates for surgical resection. They are safe, minimally invasive, efficacious and cost-effective. Radiofrequency ablation (RFA) is considered as the first line treatment in some centers, though most of the guidelines recommend it for small HCCs, where surgical resection is not feasible. In developing countries percutaneous ethanol injection (PEI) and percutaneous acetic acid injection (PAI) may be used instead of RFA. For large HCCs, advances in electrode designs and newer techniques of ablation, including microwave ablation, are increasingly been used. Combination treatment modalities have shown promising results as compared to single modality for large tumors. The selection of the most appropriate modality depends on the size, number of lesions, the liver function status, patient's financial resources, availability of a particular technique and the expertise available.
经皮局部消融(PLA)技术目前被认为是无法进行手术切除的早期肝细胞癌(HCC)患者的最佳治疗选择。它们安全、微创、有效且具有成本效益。在一些中心,射频消融(RFA)被视为一线治疗方法,尽管大多数指南推荐其用于无法进行手术切除的小肝癌。在发展中国家,可使用经皮乙醇注射(PEI)和经皮乙酸注射(PAI)替代RFA。对于大肝癌,电极设计的进展以及包括微波消融在内的更新的消融技术正越来越多地被使用。与单一治疗方式相比,联合治疗方式对大肿瘤已显示出有前景的结果。最合适治疗方式的选择取决于病变的大小、数量、肝功能状态、患者的经济资源、特定技术的可获得性以及现有的专业知识。